Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

p63 identifies keratinocyte stem cells.

G Pellegrini1, E Dellambra, O Golisano

  • 1Laboratory of Tissue Engineering IDI, Istituto Dermopatico dell'Immacolata, 00040 Rome, Italy.

Proceedings of the National Academy of Sciences of the United States of America
|March 15, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<i>HER-2</i> gene alterations as biomarker in patients with metastatic colorectal cancer treated with FOLFIRI + cetuximab: findings from the CAPRI-2 GOIM study.

ESMO gastrointestinal oncology·2026
Same author

Clinical and translational results from the phase II ABACO trial evaluating the activity of cabozantinib in pretreated patients with metastatic colorectal cancer.

ESMO gastrointestinal oncology·2026
Same author

Effectiveness of FTD/TPI plus bevacizumab and impact of prior bevacizumab exposure in patients with mCRC: the Italian FLOWER study.

ESMO gastrointestinal oncology·2026
Same author

Off-label drug use in oncology: integrating molecular and genetic analysis in an academic center's real-world approach.

ESMO real world data and digital oncology·2026
Same author

Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE-2 GOIM trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Efficacy and safety of atezolizumab plus bevacizumab in MSI-like metastatic colorectal cancer: a multicenter, single-arm, phase II, open-label clinical trial.

ESMO open·2025

The p63 transcription factor distinguishes human keratinocyte stem cells from transient amplifying cells. This finding is crucial for epithelial cell therapy and understanding epithelial tumorigenesis.

Area of Science:

  • Cell Biology
  • Developmental Biology
  • Dermatology

Background:

  • Stratified squamous epithelia contain stem and transient amplifying (TA) keratinocytes.
  • Previous research identified some polypeptides more abundant in stem cells than TA cells, but no definitive stem cell marker existed.

Purpose of the Study:

  • To identify a specific marker that distinguishes human keratinocyte stem cells from their TA progeny.
  • To investigate the role of p63 transcription factor in epithelial stem cell identification and maintenance.

Main Methods:

  • Utilized clonal analysis of human keratinocyte stem and TA cells in culture.
  • Examined the expression of p63 transcription factor in isolated cell populations (holoclones, paraclones, meroclones).
  • Investigated the role of 14-3-3 sigma protein in regulating keratinocyte stem cell behavior and p63 expression.

Related Experiment Videos

Main Results:

  • Nuclear p63 expression was identified as a marker specific to human keratinocyte stem cells.
  • p63 was abundantly expressed in holoclones (stem cell progeny) but undetectable in paraclones (TA cell progeny).
  • Transient amplifying keratinocytes (meroclones) showed greatly reduced p63 levels.
  • Down-regulation of 14-3-3 sigma protein maintained keratinocytes in the stem cell compartment and preserved p63 expression.

Conclusions:

  • p63 transcription factor serves as a reliable marker for human keratinocyte stem cells.
  • The findings have significant implications for epithelial cell therapy and research into epithelial tumorigenesis.